Explore the vast range of titles available.

Mr. [Todd Narwid] will focus on Narrowstep's long term sales and business development strategies. He joins the company with over 15 years of extensive sales and management experience. Most recently, Mr. Narwid was President of the Business Solutions Division for RCN, Inc. where he led the company in revenue, EBITDA growth and cash flow while quadrupling the business to over $75 million within an 18 month timeframe. During that time, Mr. Narwid provided the framework to develop the customer economics necessary to successfully scale the business and also implemented sales and operations processes to ensure Sarbanes Oxley compliance. Narrowstep, Inc. Chairman of the Board and interim CEO, [David C. McCourt] added \"I am thrilled to have Todd join the newly re-structured Narrowstep. He is a proven performer who will guide Narrowstep as we move forward and scale growth. Todd will bring his outstanding sales record, management and leadership skills to not only continuing the growth that the company has experienced to date, but to further expand our sales efforts and build important, strategic relationships.\"

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com is being compensated up to six thousand dollars by a third party for a HWYI advertising and promotional services. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

M2 PRESSWIRE-November 20, 2006-RealPennies: Alerts: Turning Pennies into Dollars (OTCBB: ACHM), (OTCBB: FRPT), (OTCBB: KGBC), (OTCBB: AANI) (C)1994-2006 M2 COMMUNICATIONS LTD (OTCBB: FRPT) Force Protection, Inc. recently hit a new 52 week high of 11.8 Force Protection, Inc. (OTCBB: FRPT) also recently announced its application for listing of its common stock on the NASDAQ Capital Market. The Company believes it meets all of the listing criteria except for its Board composition. ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http:// www.presswire.net on the world wide web. Inquiries to info@m2.com)).

AUSTIN - A very interesting indicator to look for is where the money is flowing into. We have a filter that we watch every morning that shows us \"Dollar Volume\". Here are a few of these stocks: Capacitive Deionization Technology Systems, Inc.(OTCBB CDTN), GreenMan Technologies, Inc. (OTCBB: GMTI), Provectus Pharmaceuticals, Inc.(OTCBB PVCT), 1st Colonial Bancorp, Inc.(OTCBB:FCOB) GreenMan Technologies, Inc. (OTCBB: GMTI) - Wednesday's shares increased 5.00% to $0.420 per share with a total of 78,000 shares traded. The company announced results for the three and twelve months ended September 30, 2006. Lyle Jensen, GreenMan's President and Chief Executive Officer stated: \"I believe today's announcement validates the decisions and direction taken over the past eight months and is the result of a great deal of dedicated commitment and work by our employees. By remaining focused and implementing our Five Step Turnaround Plan intelligently and methodically, we find ourselves almost six months ahead of the original timeline set back in May. In addition, we believe that the elimination of the historical \"going concern\" opinion from our independent public accountants, for the first time in four years, is additional evidence the turnaround plan is working.\" Mr. Jensen added, \"Our relationship with our secured lender remains strong and we are extremely proud of the fact we have self funded our operations over the past six months without drawing down a single dollar from our working capital line of credit. We remain committed to making correct decisions for the long-term benefit of GreenMan and our shareholders.\" Please join us December 14, 2006 at 2:00 PM EST for a conference call in which we will discuss the results for the quarter and fiscal year ended December 31, 2006 and provide more details about actions which have been taken and are in the process of being taken to accelerate GreenMan's financial turnaround. To participate, please call 1-800-967-7137 and ask for the GreenMan call. A replay of the conference call can be accessed until 11:30 PM on December 16, 2006 by calling 888-203-1112 and entering pass code 1106477. In September 2005, due to the magnitude of continued operating losses, our Board of Directors approved separate plans to divest the operations of our Georgia and Tennessee subsidiaries and dispose of their respective assets. In addition, due to continuing operation losses, in July 2006 we sold our California subsidiary. Accordingly, we have classified all three respective entity's results of operations as discontinued operations for all periods presented in the accompanying consolidated financial statements. Provectus Pharmaceuticals, Inc.(OTCBB PVCT) - Tuesday's market stayed the same at 0% to $1.20, with a total of 27,800 shares traded. The company announced it has received allowance of two patent applications protecting its flagship products, Provecta(TM) and Xantryl(TM), from the European Patent Office (EPO) and the Intellectual Property Office of Taiwan (TIPO). The pending patents cover certain formulations and medical uses of Provecta, a novel formulation of rose bengal, also called PV-10, as a medicament for treatment of cancer and other serious diseases, and Xantryl, a topical photoactive gel used to treat acute psoriasis and other chronic skin diseases. The Company is seeking protection of its assets in key markets worldwide, notes Provectus CEO Craig Dees, Ph.D. The two allowances are the Company's first international cases covering these product families to have completed prosecution. \"As we successfully complete clinical trials for both products and for a number of different indications, we believe that aggressively protecting those intellectual assets will be vital to our eventual marketing success,\" said Dees. \"These allowances validate the value of our science and our global intellectual property strategy to build value for our shareholders.\"